On the recordNovember 2, 2011
I thank the gentleman for being a leader. When folks think of States like California, they think of high technology and medical devices, but it's the investors who have a large component in States like California that invest in these companies. Unfortunately, the FDA has become so risk averse that the investors aren't investing the resources needed to start the new products, and that's the pipeline going over to Europe. That's the challenge we have. Someone else at the hearing a little over a week ago was my friend and colleague, Mr. Young, who also heard some of these personal stories not only from the patient perspective but the innovator perspective. I want to thank the gentleman from Indiana for his leadership and for inviting me to be a part of that hearing in Indiana.
